The Effectiveness of Combined Local and Systemic Methotrexate Treatment in Cesarean Scar Pregnancy Weeks 8 to 14.

IF 1.4 Q3 OBSTETRICS & GYNECOLOGY

Gynecology and Minimally Invasive Therapy-GMIT Pub Date : 2023-08-10 eCollection Date: 2023-07-01 DOI:10.4103/gmit.gmit_135_22

Xuyen Van, Thuong Bui, Hoang The Dinh, Thong Van, Anh Tran

{"title":"The Effectiveness of Combined Local and Systemic Methotrexate Treatment in Cesarean Scar Pregnancy Weeks 8 to 14.","authors":"Xuyen Van, Thuong Bui, Hoang The Dinh, Thong Van, Anh Tran","doi":"10.4103/gmit.gmit_135_22","DOIUrl":null,"url":null,"abstract":"Objectives: This study aims to identify the success rate and correlated factors of combined local and systemic methotrexate (MTX) injection treatment in cesarean scar pregnancy (CSP).Materials and methods: The combined local and systemic MTX administration has been used for CSP weeks 8-14 at Tu Du Maternal Hospital; however, its effectiveness and correlated factors have not been closely investigated. This is a retrospective case series of 123 CSP patients between 8 and 14 weeks of gestation who were treated at Tu Du Hospital from the year 2016 to 2020.Results: The success rate, uterine-sparing rate, and side effects of MTX treatment are 50.4%, 95%, and 17.2%, respectively. The factors related to treatment failure with statistical significance included gestational age (odds ratio [OR] = 3.99), residual myometrial thickness >3 mm (OR = 0.37), and postprocedure gestational sac diameter (OR = 1.09).Conclusion: Combined local and systemic MTX injection is minimally invasive and effective in CSP weeks 8-14. Therefore, it should be utilized routinely.","PeriodicalId":45272,"journal":{"name":"Gynecology and Minimally Invasive Therapy-GMIT","volume":"12 3","pages":"170-174"},"PeriodicalIF":1.4000,"publicationDate":"2023-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/69/1f/GMIT-12-170.PMC10553595.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecology and Minimally Invasive Therapy-GMIT","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/gmit.gmit_135_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study aims to identify the success rate and correlated factors of combined local and systemic methotrexate (MTX) injection treatment in cesarean scar pregnancy (CSP).

Materials and methods: The combined local and systemic MTX administration has been used for CSP weeks 8-14 at Tu Du Maternal Hospital; however, its effectiveness and correlated factors have not been closely investigated. This is a retrospective case series of 123 CSP patients between 8 and 14 weeks of gestation who were treated at Tu Du Hospital from the year 2016 to 2020.

Results: The success rate, uterine-sparing rate, and side effects of MTX treatment are 50.4%, 95%, and 17.2%, respectively. The factors related to treatment failure with statistical significance included gestational age (odds ratio [OR] = 3.99), residual myometrial thickness >3 mm (OR = 0.37), and postprocedure gestational sac diameter (OR = 1.09).

Conclusion: Combined local and systemic MTX injection is minimally invasive and effective in CSP weeks 8-14. Therefore, it should be utilized routinely.

Abstract Image

查看原文本刊更多论文

局部和全身甲氨蝶呤联合治疗剖宫产瘢痕妊娠8-14周的疗效。

目的：探讨局部和全身联合注射甲氨蝶呤（MTX）治疗剖宫产瘢痕妊娠（CSP）的成功率及相关因素；然而，其有效性及其相关因素尚未得到密切研究。这是一个回顾性病例系列，包括2016年至2020年在屠都医院接受治疗的123名妊娠8至14周的CSP患者。结果：MTX治疗的成功率、子宫保留率和副作用分别为50.4%、95%和17.2%。具有统计学意义的与治疗失败相关的因素包括胎龄（比值比[OR]=3.99）、残余肌层厚度>3mm（OR=0.37）和术后孕囊直径（OR=1.09）。因此，应该经常使用它。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecology and Minimally Invasive Therapy-GMIT OBSTETRICS & GYNECOLOGY-

CiteScore

2.00

自引率

16.70%

发文量

审稿时长

52 weeks